NasdaqGS:GHHealthcare
Is Guardant Health (GH) A Bargain Following Its Patent Verdict Setback?
Guardant Health (GH) is in focus after a U.S. District Court upheld a major patent infringement verdict, imposing over US$245.2m in damages plus 6% ongoing royalties on 11 key products.
See our latest analysis for Guardant Health.
Guardant Health shares have been volatile around the patent ruling, with the stock down 4.4% on the day but still showing a 10.8% 1 month share price return and a very large 1 year total shareholder return. This suggests momentum has been building despite the legal...